Date: 2016-04-01
Type of information: R&D agreement
Compound: therapeutic peptide based on the CP&IP (Cell Penetrating & Interfering Peptides) platform
Company: PEP Therapy (France) Conectus Alsace (France)
Therapeutic area: Metabolic diseases
Type agreement: R&D
Action mechanism: peptide. The CPP (Cell Penetrating Peptides) platform is used as a shuttle to deliver drugs into the cell. These short interfering peptides are designed to specifically block relevant protein/protein interactions, thus inhibiting pathological mechanisms.
Disease: type 2 diabetes
Details: * On April 1, 2016, PEP-Therapy and Conectus Alsace announced that they have joined forces to develope a new targeted therapeutic peptide for type 2 diabetes. The DiabetAlms project is led by Vincent Marion from the laboratory of medical genetics in Strasbourg (UMRS-1112 ; Unistra-Inserm - Institut de Génétique Médicale d’Alsace). Conectus Alsace will invest more than 400k€ in this project. PEP-Therapy will use its CP&IP (Cell Penetrating & Interfering Peptides) platform to design and develop a new therapeutic peptide directed against the specific target identified by Vincent Marion and Pr. Nikolai Petrovsky. PEP-Therapy has an exclusive option to license the drug candidates generated in the course of the collaboration.
Financial terms:
Latest news:
